Symptom-based stratification of patients with primary Sjogren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials.

Tarn, JR.; Howard-Tripp, N.; Lendrem, DW.; Mariette, X.; Saraux, A.; Devauchelle-Pensec, V.; Seror, R.; Skelton, AJ.; James, K.; McMeekin, P.; Al-Ali, S.; Hackett, KL.; Lendrem, BC.; Hargreaves, B.; Casement, J.; Mitchell, S.; Bowman, SJ.; Price, E.; Pease, CT.; Emery, P.; Lanyon, P.; Hunter, J.; Gupta, M.; Bombardieri, M.; Sutcliffe, N.; Pitzalis, C.; McLaren, J.; Cooper, A.; Regan, M.; Giles, I.; Isenberg, D.; Saravanan, V.; Coady, D.; Dasgupta, B.; McHugh, N.; Young-Min, S.; Moots, R.; Gendi, N.; Akil, M.; Griffiths, B.; Johnsen, SJA.; Norheim, KB.; Omdal, R.; Stocken, D.; Everett, C.; Fernandez, C.; Isaacs, JD.; Gottenberg, JE.; Ng, WF.

Symptom-based stratification of patients with primary Sjogren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials.

All Authors

Tarn, JR.

Howard-Tripp, N.

Lendrem, DW.

Mariette, X.

Saraux, A.

Devauchelle-Pensec, V.

Seror, R.

Skelton, AJ.

James, K.

McMeekin, P.

Show 10 more

LTHT Author

Pease, Colin
Emery, Paul

LTHT Department

NIHR Leeds Biomedical Research Centre
Rheumatology

Publication Date

2019

Item Type

Journal Article

Abstract

BACKGROUND: Heterogeneity is a major obstacle to developing effective treatments for patients with primary Sjogren's syndrome. We aimed to develop a robust method for stratification, exploiting heterogeneity in patient-reported symptoms, and to relate these differences to pathobiology and therapeutic response. METHODS: We did hierarchical cluster analysis using five common symptoms associated with primary Sjogren's syndrome (pain, fatigue, dryness, anxiety, and depression), followed by multinomial logistic regression to identify subgroups in the UK Primary Sjogren's Syndrome Registry (UKPSSR). We assessed clinical and biological differences between these subgroups, including transcriptional differences in peripheral blood. Patients from two independent validation cohorts in Norway and France were used to confirm patient stratification. Data from two phase 3 clinical trials were similarly stratified to assess the differences between subgroups in treatment response to hydroxychloroquine and rituximab. FINDINGS: In the UKPSSR cohort (n=608), we identified four subgroups: Low symptom burden (LSB), high symptom burden (HSB), dryness dominant with fatigue (DDF), and pain dominant with fatigue (PDF). Significant differences in peripheral blood lymphocyte counts, anti-SSA and anti-SSB antibody positivity, as well as serum IgG, kappa-free light chain, beta2-microglobulin, and CXCL13 concentrations were observed between these subgroups, along with differentially expressed transcriptomic modules in peripheral blood. Similar findings were observed in the independent validation cohorts (n=396). Reanalysis of trial data stratifying patients into these subgroups suggested a treatment effect with hydroxychloroquine in the HSB subgroup and with rituximab in the DDF subgroup compared with placebo. INTERPRETATION: Stratification on the basis of patient-reported symptoms of patients with primary Sjogren's syndrome revealed distinct pathobiological endotypes with distinct responses to immunomodulatory treatments. Our data have important implications for clinical management, trial design, and therapeutic development. Similar stratification approaches might be useful for patients with other chronic immune-mediated diseases. FUNDING: UK Medical Research Council, British Sjogren's Syndrome Association, French Ministry of Health, Arthritis Research UK, Foundation for Research in Rheumatology. VIDEO ABSTRACT.